Cargando…

CDK4/6 inhibition stabilizes disease in patients with p16-null non-small cell lung cancer and is synergistic with mTOR inhibition

Aberrant activation of CDK4/6 kinase is the most common somatic event in non-small cell lung cancer (NSCLC). Palbociclib is a highly specific CDK4/6 inhibitor shown to inhibit cell cycle progression and promote cellular senescence. We conducted a phase 2 clinical trial of palbociclib in 19 previousl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gopalan, Priya K., Villegas, Andres Gordillo, Cao, Chunxia, Pinder-Schenck, Mary, Chiappori, Alberto, Hou, Wei, Zajac-Kaye, Maria, Ivey, Alison M., Kaye, Frederic J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Priority Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6324768/ https://www.ncbi.nlm.nih.gov/pubmed/30647837 http://dx.doi.org/10.18632/oncotarget.26424

Ejemplares similares

Combined inhibition of PIM and CDK4/6 suppresses both mTOR signaling and Rb phosphorylation and potentiates PI3K inhibition in cancer cells
por: Litchfield, Lacey M., et al.
Publicado: (2020)

Inhibition of mTOR-kinase destabilizes MYCN and is a potential therapy for MYCN-dependent tumors
por: Vaughan, Lynsey, et al.
Publicado: (2016)

Intrinsic resistance to PIM kinase inhibition in AML through p38α-mediated feedback activation of mTOR signaling
por: Brunen, Diede, et al.
Publicado: (2016)

The nuclear import of ribosomal proteins is regulated by mTOR
por: Kazyken, Dubek, et al.
Publicado: (2014)

Dual Inhibition of KRAS(G12D) and Pan-ERBB Is Synergistic in Pancreatic Ductal Adenocarcinoma
por: Gulay, Kevin Christian Montecillo, et al.
Publicado: (2023)

MCL-1-independent mechanisms of synergy between dual PI3K/mTOR and BCL-2 inhibition in diffuse large B cell lymphoma
por: Lee, J. Scott, et al.
Publicado: (2015)

Point mutations of the mTOR-RHEB pathway in renal cell carcinoma
por: Ghosh, Arindam P., et al.
Publicado: (2015)

A unifying gene signature for adenoid cystic cancer identifies parallel MYB-dependent and MYB-independent therapeutic targets
por: Gao, Ruli, et al.
Publicado: (2014)

The interplay of CDK4 and CDK6 in melanoma
por: Kollmann, Karoline, et al.
Publicado: (2019)

Defining the transcriptional and biological response to CDK4/6 inhibition in relation to ER+/HER2- breast cancer
por: Knudsen, Erik S., et al.
Publicado: (2016)

Regulation of mTOR complexes in long-lived growth hormone receptor knockout and Snell dwarf mice
por: Shi, Xiaofang, et al.
Publicado: (2022)

Inhibition of CDK8 mediator kinase suppresses estrogen dependent transcription and the growth of estrogen receptor positive breast cancer
por: McDermott, Martina S.J., et al.
Publicado: (2017)

Synergistic efficacy of inhibiting MYCN and mTOR signaling against neuroblastoma
por: Kling, Matthew J., et al.
Publicado: (2021)

Targeting of hyperactivated mTOR signaling in high-risk acute lymphoblastic leukemia in a pre-clinical model
por: Hasan, Md. Nabiul, et al.
Publicado: (2014)

Retinoblastoma cells activate the AKT pathway and are vulnerable to the PI3K/mTOR inhibitor NVP-BEZ235
por: Xie, Chencheng, et al.
Publicado: (2017)

Overactive mTOR signaling leads to endometrial hyperplasia in aged women and mice
por: Bajwa, Preety, et al.
Publicado: (2016)

Novel combinations of PI3K-mTOR inhibitors with dacomitinib or chemotherapy in PTEN-deficient patient-derived tumor xenografts
por: Brana, Irene, et al.
Publicado: (2017)

Cyclopamine and Rapamycin Synergistically Inhibit mTOR Signalling in Mouse Hepatocytes, Revealing an Interaction of Hedgehog and mTor Signalling in the Liver
por: Spormann, Luise, et al.
Publicado: (2020)

Combined HASPIN and mTOR inhibition is synergistic against KRAS-driven carcinomas
por: Xu, Chenyue, et al.
Publicado: (2022)

Palbociclib resistance confers dependence on an FGFR-MAP kinase-mTOR-driven pathway in KRAS-mutant non-small cell lung cancer
por: Haines, Eric, et al.
Publicado: (2018)

A synthetic-lethality RNAi screen reveals an ERK-mTOR co-targeting pro-apoptotic switch in PIK3CA(+) oral cancers
por: Yamaguchi, Kosuke, et al.
Publicado: (2016)

The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition
por: Haagensen, E J, et al.
Publicado: (2012)

Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells
por: Grabinski, Nicole, et al.
Publicado: (2012)

FUS contributes to mTOR-dependent inhibition of translation
por: Sévigny, Myriam, et al.
Publicado: (2021)

Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34(+) proliferating and quiescent chronic myeloid leukemia blast crisis cells
por: Carter, Bing Z., et al.
Publicado: (2015)

Overcoming resistance to single-agent therapy for oncogenic BRAF gene fusions via combinatorial targeting of MAPK and PI3K/mTOR signaling pathways
por: Jain, Payal, et al.
Publicado: (2017)

Vertical inhibition of the PI3K/Akt/mTOR pathway is synergistic in breast cancer
por: Woo, S-U, et al.
Publicado: (2017)

Loss of p16(INK4A) stimulates aberrant mitochondrial biogenesis through a CDK4/Rb-independent pathway
por: Tyagi, Ethika, et al.
Publicado: (2017)

Escaping mTOR inhibition for cancer therapy: Tumor suppressor functions of mTOR
por: Villar, Victor H., et al.
Publicado: (2017)

Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells()
por: Bonelli, Mara A., et al.
Publicado: (2017)

AKT/mTOR signaling modulates resistance to endocrine therapy and CDK4/6 inhibition in metastatic breast cancers
por: Abu-Khalaf, Maysa M., et al.
Publicado: (2023)

Selective impact of CDK4/6 suppression on patient-derived models of pancreatic cancer
por: Witkiewicz, Agnieszka K., et al.
Publicado: (2015)

Enhanced activity of the CREB co-activator Crtc1 in LKB1 null lung cancer
por: Komiya, Takefumi, et al.
Publicado: (2009)

Comparison of SARS-CoV-2 RT-PCR on a high-throughput molecular diagnostic platform and the cobas SARS-CoV-2 test for the diagnostic of COVID-19 on various clinical samples
por: Opota, Onya, et al.
Publicado: (2020)

α-Ketoglutarate inhibits autophagy
por: Baracco, Elisa Elena, et al.
Publicado: (2019)

Beneficial bacteria inhibit cachexia
por: Varian, Bernard J., et al.
Publicado: (2016)

Targeting both IGF-1R and mTOR synergistically inhibits growth of renal cell carcinoma in vitro
por: Cardillo, Thomas M, et al.
Publicado: (2013)

AAA + ATPase Thorase inhibits mTOR signaling through the disassembly of the mTOR complex 1
por: Umanah, George K. E., et al.
Publicado: (2022)

CDK1 promotes nascent DNA synthesis and induces resistance of cancer cells to DNA-damaging therapeutic agents
por: Liao, Hongwei, et al.
Publicado: (2017)

Biological specificity of CDK4/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature
por: Knudsen, Erik S., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_lsp8bf1froe77e2m62ssf07nau